Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Shin Nippon Biomedical Laboratories's average EBITDA Per Share Growth Rate was 13.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 1.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.90% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 23.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Shin Nippon Biomedical Laboratories was 153.90% per year. The lowest was -36.80% per year. And the median was 9.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Shin Nippon Biomedical Laboratories 3-Year EBITDA Growth Rate Related Terms
SBLOF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 1.70% mean?
Shin Nippon Biomedical Laboratories (SBLOF) has a 3-Year EBITDA Growth Rate of 1.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shin Nippon Biomedical Laboratories and its competitors. This is 82% below median its historical median of 9.40. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #103 out of 166 companies in the Medical Diagnostics & Research industry, placing it in the top 62%.
Is Shin Nippon Biomedical Laboratories' 3-Year EBITDA Growth Rate too high?
Shin Nippon Biomedical Laboratories' current 3-Year EBITDA Growth Rate of 1.70% is 82% below median its 10-year median of 9.40. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 10.80. Shin Nippon Biomedical Laboratories' value of 1.70% is 84.3% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #103 out of 166 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #103 out of 166 companies for 3-Year EBITDA Growth Rate. This places Shin Nippon Biomedical Laboratories in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.80. Shin Nippon Biomedical Laboratories' value of 1.70% is 84.3% below this benchmark. While the company's 10-year median is 9.40 vs. the industry median of 10.80, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.80, based on 166 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current 3-Year EBITDA Growth Rate of 1.70% is 84.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current 3-Year EBITDA Growth Rate is 1.70%, which is 82% below median its own 10-year median of 9.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current 3-Year EBITDA Growth Rate of 1.70%. The stock's GF Value™ is $12.83, compared to a current price of $9.16 — trading 28.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 1.70%, which is 82% below median its 10-year median of 9.40 and 84.3% below the Medical Diagnostics & Research industry median of 10.80. Shin Nippon Biomedical Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current 3-Year EBITDA Growth Rate is 1.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 28.6% below its estimated GF Value™ of $12.83.
Key valuation signals for SBLOF:
3-Year EBITDA Growth Rate: 1.70% (82% below median its 10-year median of 9.40)
GF Value™: $12.83 vs. price of $9.16 (28.6% below fair value)
Industry Position: 84.3% below the Medical Diagnostics & Research median (#103 of 166)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score
Get the complete analysis for SBLOF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
